The role of centre and country factors on process and outcome indicators in critically ill patients with hospital-acquired bloodstream infections
© 2024. The Author(s)..
PURPOSE: The primary objective of this study was to evaluate the associations between centre/country-based factors and two important process and outcome indicators in patients with hospital-acquired bloodstream infections (HABSI).
METHODS: We used data on HABSI from the prospective EUROBACT-2 study to evaluate the associations between centre/country factors on a process or an outcome indicator: adequacy of antimicrobial therapy within the first 24 h or 28-day mortality, respectively. Mixed logistical models with clustering by centre identified factors associated with both indicators.
RESULTS: Two thousand two hundred nine patients from two hundred one intensive care units (ICUs) were included in forty-seven countries. Overall, 51% (n = 1128) of patients received an adequate antimicrobial therapy and the 28-day mortality was 38% (n = 839). The availability of therapeutic drug monitoring (TDM) for aminoglycosides everyday [odds ratio (OR) 1.48, 95% confidence interval (CI) 1.03-2.14] or within a few hours (OR 1.79, 95% CI 1.34-2.38), surveillance cultures for multidrug-resistant organism carriage performed weekly (OR 1.45, 95% CI 1.09-1.93), and increasing Human Development Index (HDI) values were associated with adequate antimicrobial therapy. The presence of intermediate care beds (OR 0.63, 95% CI 0.47-0.84), TDM for aminoglycoside available everyday (OR 0.66, 95% CI 0.44-1.00) or within a few hours (OR 0.51, 95% CI 0.37-0.70), 24/7 consultation of clinical pharmacists (OR 0.67, 95% CI 0.47-0.95), percentage of vancomycin-resistant enterococci (VRE) between 10% and 25% in the ICU (OR 1.67, 95% CI 1.00-2.80), and decreasing HDI values were associated with 28-day mortality.
CONCLUSION: Centre/country factors should be targeted for future interventions to improve management strategies and outcome of HABSI in ICU patients.
| Errataetall: |
ErratumIn: Intensive Care Med. 2024 Apr 8;:. - PMID 38587556 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Intensive care medicine - (2024) vom: 18. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Buetti, Niccolò [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bacteraemia |
|---|
| Anmerkungen: |
Date Revised 08.04.2024 published: Print-Electronic ErratumIn: Intensive Care Med. 2024 Apr 8;:. - PMID 38587556 Citation Status Publisher |
|---|
| doi: |
10.1007/s00134-024-07348-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369878701 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369878701 | ||
| 003 | DE-627 | ||
| 005 | 20240408232737.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240319s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00134-024-07348-0 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1369.xml |
| 035 | |a (DE-627)NLM369878701 | ||
| 035 | |a (NLM)38498170 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Buetti, Niccolò |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The role of centre and country factors on process and outcome indicators in critically ill patients with hospital-acquired bloodstream infections |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 08.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ErratumIn: Intensive Care Med. 2024 Apr 8;:. - PMID 38587556 | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a PURPOSE: The primary objective of this study was to evaluate the associations between centre/country-based factors and two important process and outcome indicators in patients with hospital-acquired bloodstream infections (HABSI) | ||
| 520 | |a METHODS: We used data on HABSI from the prospective EUROBACT-2 study to evaluate the associations between centre/country factors on a process or an outcome indicator: adequacy of antimicrobial therapy within the first 24 h or 28-day mortality, respectively. Mixed logistical models with clustering by centre identified factors associated with both indicators | ||
| 520 | |a RESULTS: Two thousand two hundred nine patients from two hundred one intensive care units (ICUs) were included in forty-seven countries. Overall, 51% (n = 1128) of patients received an adequate antimicrobial therapy and the 28-day mortality was 38% (n = 839). The availability of therapeutic drug monitoring (TDM) for aminoglycosides everyday [odds ratio (OR) 1.48, 95% confidence interval (CI) 1.03-2.14] or within a few hours (OR 1.79, 95% CI 1.34-2.38), surveillance cultures for multidrug-resistant organism carriage performed weekly (OR 1.45, 95% CI 1.09-1.93), and increasing Human Development Index (HDI) values were associated with adequate antimicrobial therapy. The presence of intermediate care beds (OR 0.63, 95% CI 0.47-0.84), TDM for aminoglycoside available everyday (OR 0.66, 95% CI 0.44-1.00) or within a few hours (OR 0.51, 95% CI 0.37-0.70), 24/7 consultation of clinical pharmacists (OR 0.67, 95% CI 0.47-0.95), percentage of vancomycin-resistant enterococci (VRE) between 10% and 25% in the ICU (OR 1.67, 95% CI 1.00-2.80), and decreasing HDI values were associated with 28-day mortality | ||
| 520 | |a CONCLUSION: Centre/country factors should be targeted for future interventions to improve management strategies and outcome of HABSI in ICU patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Bacteraemia | |
| 650 | 4 | |a Centre | |
| 650 | 4 | |a Hospital-acquired bloodstream infections | |
| 650 | 4 | |a Outcome indicator | |
| 650 | 4 | |a Process indicator | |
| 700 | 1 | |a Tabah, Alexis |e verfasserin |4 aut | |
| 700 | 1 | |a Setti, Nour |e verfasserin |4 aut | |
| 700 | 1 | |a Ruckly, Stéphane |e verfasserin |4 aut | |
| 700 | 1 | |a Barbier, François |e verfasserin |4 aut | |
| 700 | 1 | |a Akova, Murat |e verfasserin |4 aut | |
| 700 | 1 | |a Aslan, Abdullah Tarik |e verfasserin |4 aut | |
| 700 | 1 | |a Leone, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Bassetti, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Morris, Andrew Conway |e verfasserin |4 aut | |
| 700 | 1 | |a Arvaniti, Kostoula |e verfasserin |4 aut | |
| 700 | 1 | |a Paiva, José-Artur |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrer, Ricard |e verfasserin |4 aut | |
| 700 | 1 | |a Qiu, Haibo |e verfasserin |4 aut | |
| 700 | 1 | |a Montrucchio, Giorgia |e verfasserin |4 aut | |
| 700 | 1 | |a Cortegiani, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Kayaaslan, Bircan |e verfasserin |4 aut | |
| 700 | 1 | |a De Bus, Liesbet |e verfasserin |4 aut | |
| 700 | 1 | |a De Waele, Jan J |e verfasserin |4 aut | |
| 700 | 1 | |a Timsit, Jean-François |e verfasserin |4 aut | |
| 700 | 0 | |a EUROBACT-2 Study Group, the European Society of Intensive Care Medicine (ESICM), the European Society of Clinical Microbiology, the Infectious Diseases (ESCMID) Study Group for Infections in Critically Ill Patients (ESGCIP), and the OUTCOMEREA Network |e verfasserin |4 aut | |
| 700 | 1 | |a Tabah, Alexis |e investigator |4 oth | |
| 700 | 1 | |a Lipman, Jeffrey |e investigator |4 oth | |
| 700 | 1 | |a Pollock, Hamish |e investigator |4 oth | |
| 700 | 1 | |a Margetts, Ben |e investigator |4 oth | |
| 700 | 1 | |a Udy, Andrew |e investigator |4 oth | |
| 700 | 1 | |a Young, Meredith |e investigator |4 oth | |
| 700 | 1 | |a Bhadange, Neeraj |e investigator |4 oth | |
| 700 | 1 | |a Tyler, Steven |e investigator |4 oth | |
| 700 | 1 | |a Ledtischke, Anne |e investigator |4 oth | |
| 700 | 1 | |a Finnis, Mackenzie |e investigator |4 oth | |
| 700 | 1 | |a Dwivedi, Jyotsna |e investigator |4 oth | |
| 700 | 1 | |a Saxena, Manoj |e investigator |4 oth | |
| 700 | 1 | |a Biradar, Vishwanath |e investigator |4 oth | |
| 700 | 1 | |a Soar, Natalie |e investigator |4 oth | |
| 700 | 1 | |a Sarode, Vineet |e investigator |4 oth | |
| 700 | 1 | |a Brewster, David |e investigator |4 oth | |
| 700 | 1 | |a Regli, Adrian |e investigator |4 oth | |
| 700 | 1 | |a Weeda, Elizabeth |e investigator |4 oth | |
| 700 | 1 | |a Ahmed, Samiul |e investigator |4 oth | |
| 700 | 1 | |a Fourie, Cheryl |e investigator |4 oth | |
| 700 | 1 | |a Laupland, Kevin |e investigator |4 oth | |
| 700 | 1 | |a Ramanan, Mahesh |e investigator |4 oth | |
| 700 | 1 | |a Walsham, James |e investigator |4 oth | |
| 700 | 1 | |a Meyer, Jason |e investigator |4 oth | |
| 700 | 1 | |a Litton, Edward |e investigator |4 oth | |
| 700 | 1 | |a Palermo, Anna Maria |e investigator |4 oth | |
| 700 | 1 | |a Yap, Timothy |e investigator |4 oth | |
| 700 | 1 | |a Eroglu, Ege |e investigator |4 oth | |
| 700 | 1 | |a Attokaran, Antony George |e investigator |4 oth | |
| 700 | 1 | |a Jaramillo, C'havala |e investigator |4 oth | |
| 700 | 1 | |a Nafees, Khalid Mahmood Khan |e investigator |4 oth | |
| 700 | 1 | |a Rashid, Nurhikmahtul Aqilah Haji Abd |e investigator |4 oth | |
| 700 | 1 | |a Walid, Haji Adi Muhamad Ibnu |e investigator |4 oth | |
| 700 | 1 | |a Mon, Tomas |e investigator |4 oth | |
| 700 | 1 | |a Moorthi, Dhakshina |e investigator |4 oth | |
| 700 | 1 | |a Sudhirchandra, Shah |e investigator |4 oth | |
| 700 | 1 | |a Sridharan, Dhadappa Damodar |e investigator |4 oth | |
| 700 | 1 | |a Haibo, Qiu |e investigator |4 oth | |
| 700 | 1 | |a Xie, Jianfeng |e investigator |4 oth | |
| 700 | 1 | |a Wei-Hua, Lu |e investigator |4 oth | |
| 700 | 1 | |a Zhen, Wang |e investigator |4 oth | |
| 700 | 1 | |a Qian, Chuanyun |e investigator |4 oth | |
| 700 | 1 | |a Luo, Jili |e investigator |4 oth | |
| 700 | 1 | |a Chen, Xiaomei |e investigator |4 oth | |
| 700 | 1 | |a Wang, Hao |e investigator |4 oth | |
| 700 | 1 | |a Zhao, Peng |e investigator |4 oth | |
| 700 | 1 | |a Zhao, Juan |e investigator |4 oth | |
| 700 | 1 | |a Wusi, Qiu |e investigator |4 oth | |
| 700 | 1 | |a Mingmin, Chen |e investigator |4 oth | |
| 700 | 1 | |a Xu, Lei |e investigator |4 oth | |
| 700 | 1 | |a Yin, Chengfen |e investigator |4 oth | |
| 700 | 1 | |a Wang, Ruilan |e investigator |4 oth | |
| 700 | 1 | |a Wang, Jinfeng |e investigator |4 oth | |
| 700 | 1 | |a Yin, Yongjie |e investigator |4 oth | |
| 700 | 1 | |a Zhang, Min |e investigator |4 oth | |
| 700 | 1 | |a Ye, Jilu |e investigator |4 oth | |
| 700 | 1 | |a Hu, Chungfang |e investigator |4 oth | |
| 700 | 1 | |a Zhou, Suming |e investigator |4 oth | |
| 700 | 1 | |a Huang, Min |e investigator |4 oth | |
| 700 | 1 | |a Yan, Jing |e investigator |4 oth | |
| 700 | 1 | |a Wang, Yan |e investigator |4 oth | |
| 700 | 1 | |a Qin, Bingyu |e investigator |4 oth | |
| 700 | 1 | |a Ye, Ling |e investigator |4 oth | |
| 700 | 1 | |a Weifeng, Xie |e investigator |4 oth | |
| 700 | 1 | |a Peije, Li |e investigator |4 oth | |
| 700 | 1 | |a Geng, Nan |e investigator |4 oth | |
| 700 | 1 | |a Ling, Lowell |e investigator |4 oth | |
| 700 | 1 | |a Hayashi, Yoshiro |e investigator |4 oth | |
| 700 | 1 | |a Karumai, Toshiyuki |e investigator |4 oth | |
| 700 | 1 | |a Yamasaki, Masaki |e investigator |4 oth | |
| 700 | 1 | |a Hashimoto, Satoru |e investigator |4 oth | |
| 700 | 1 | |a Hosokawa, Koji |e investigator |4 oth | |
| 700 | 1 | |a Makino, Jun |e investigator |4 oth | |
| 700 | 1 | |a Matsuyoshi, Takeo |e investigator |4 oth | |
| 700 | 1 | |a Kuriyama, Akira |e investigator |4 oth | |
| 700 | 1 | |a Shigemitsu, Hidenobu |e investigator |4 oth | |
| 700 | 1 | |a Mishima, Yuka |e investigator |4 oth | |
| 700 | 1 | |a Nagashima, Michio |e investigator |4 oth | |
| 700 | 1 | |a Yoshida, Hideki |e investigator |4 oth | |
| 700 | 1 | |a Fujitani, Shigeki |e investigator |4 oth | |
| 700 | 1 | |a Omori, Koichiro |e investigator |4 oth | |
| 700 | 1 | |a Rinka, Hiroshi |e investigator |4 oth | |
| 700 | 1 | |a Saito, Hiroki |e investigator |4 oth | |
| 700 | 1 | |a Atobe, Kaori |e investigator |4 oth | |
| 700 | 1 | |a Kato, Hideaki |e investigator |4 oth | |
| 700 | 1 | |a Takaki, Shunsuke |e investigator |4 oth | |
| 700 | 1 | |a Sulaiman, Helmi |e investigator |4 oth | |
| 700 | 1 | |a Hasan, M Shahnaz |e investigator |4 oth | |
| 700 | 1 | |a Jamaluddin, Muhamad Fadhil Hadi |e investigator |4 oth | |
| 700 | 1 | |a Pheng, Lee See |e investigator |4 oth | |
| 700 | 1 | |a Visvalingam, Sheshendrasurian |e investigator |4 oth | |
| 700 | 1 | |a Liew, Mun Thing |e investigator |4 oth | |
| 700 | 1 | |a Wong, Siong Ling Danny |e investigator |4 oth | |
| 700 | 1 | |a Fong, Kean Khang |e investigator |4 oth | |
| 700 | 1 | |a Rahman, Hamizah Bt Abdul |e investigator |4 oth | |
| 700 | 1 | |a Noor, Zuraini Md |e investigator |4 oth | |
| 700 | 1 | |a Tong, Lee Kok |e investigator |4 oth | |
| 700 | 1 | |a Azman, Abd Hamid |e investigator |4 oth | |
| 700 | 1 | |a Mazlan, Mohd Zulfakar |e investigator |4 oth | |
| 700 | 1 | |a Ali, Saedah |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Intensive care medicine |d 1993 |g (2024) vom: 18. März |w (DE-627)NLM000234818 |x 1432-1238 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:18 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00134-024-07348-0 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 18 |c 03 | ||